InSilicoTrials.com is a web-based platform, which provides a user-friendly computational modeling and simulation environment where many integrated easy-to-use in silico tools are readily available. The platform targets primarily users from the medical devices and pharmaceutical sectors. The in silico tools available for medical devices enable computational testing in different biomedical areas like radiology, orthopedics and cardiovascular during product design, development and validation processes. For the pharmaceutical sector, the platform provides access to in silico tools developed at all stages of the drug discovery and development processes and for many different therapeutic areas. The platform further ensures users management, content protection, simulation solvers, a validated environment, IT security, results reporting, pay-per-use licenses, the computational power of cloud machines and cloud storage.
In 2022, InSilicoTrials revenue run rate hit $1.3M in revenue.
InSilicoTrials hit $1.3M in revenue in 2021
InSilicoTrials launched in 2016 with $0 revenue
InSilicoTrials Funding History
InSilicoTrials has 15 total employees They have 55200 customers an engineering team of 2
|Total team size||15|
I am a serial entrepreneur. With a background in the cybersecurity and IT-cloud sectors, a few years ago, decided to invest in healthcare by purchasing a small digital CRO (Contract Research Organization). I saw that pharma and Medtech were facing the same problems I had already solved in my career, so I founded InSilicoTrials Technologies and made it my mission to help the industry digitalize R&D and deliver better and safer cures, in a shorter timeframe, while saving money. To do that, I built close relationships with regulatory bodies, companies and associations like the Avicenna Alliance, where I lead the Good Simulation Practice for healthcare initiative. I believe that the healthcare industry is at a pivotal crossroad. We all know that R&D costs are rising year over year and became unsustainable for most of the players, putting innovation at risk. On top of that, the long certification/registration process is eroding the time on the market for which these costs can be recovered. In the meanwhile, patients desperately need better cures. Digitalization is seen as a possible solution, that already worked in other safety-critical industries, but the implementation is a huge challenge to face. I’ve built a team with a unique mix of competencies in computational science, drugs development, engineering, regulatory approval, and IT to put together a unique solution with a goal: De-risk and accelerate R&D and regulatory approval of medicines and medical devices through a game-changing approach to modeling and simulation. InSilicoTrials Technology makes it easy for scientists, researchers, and doctors to use the incredible knowledge developed in universities and research centers all over the world by collecting them on a web-based platform. Now there is a single stop point to use them, and our technology is making it so simple that they don’t need to be simulation experts to do it, but they can learn in a matter of minutes.
What`s your age?
Favorite online tool?
Advice for 20 year old self
InSilicoTrials has 55K customers.
Average Annual Price
InSilicoTrials has an annual churn rate of 0.00%.
Gross Annual Dollar Churn
Annual Dollar Expansion
Net Revenue Retention
Rule of 40
InSilicoTrials Board of Directors
Frequently Asked Questions about InSilicoTrials
When was InSilicoTrials founded?
InSilicoTrials was founded in 2016.
How much revenue does InSilicoTrials generate?
InSilicoTrials generates $1.3M in revenue.
Who is the CEO of InSilicoTrials?
The CEO of InSilicoTrials is Luca Emili.
How much funding does InSilicoTrials have?
InSilicoTrials raised $0.
How many employees does InSilicoTrials have?
InSilicoTrials has 15 employees.
Where is InSilicoTrials headquarters?
InSilicoTrials is headquartered in Italy